Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $94 | $72 | $73 | $76 |
| % Growth | 30.5% | -1.3% | -4% | – |
| Cost of Goods Sold | $36 | $34 | $33 | $34 |
| Gross Profit | $59 | $39 | $40 | $42 |
| % Margin | 62.2% | 53.5% | 54.2% | 54.7% |
| R&D Expenses | $19 | $13 | $16 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $19 | $16 | $15 | $16 |
| Sales & Mktg Exp. | $0 | $16 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $37 | $29 | $32 | $25 |
| Operating Income | $21 | $10 | $8 | $17 |
| % Margin | 22.4% | 13.2% | 11% | 22.4% |
| Other Income/Exp. Net | -$2 | $0 | -$1 | -$3 |
| Pre-Tax Income | $19 | $10 | $7 | $14 |
| Tax Expense | $5 | $2 | $1 | $4 |
| Net Income | $14 | $8 | $5 | $10 |
| % Margin | 14.8% | 11.1% | 7.5% | 12.6% |
| EPS | 365.42 | 212.66 | 144.79 | 251.44 |
| % Growth | 71.8% | 46.9% | -42.4% | – |
| EPS Diluted | 365.42 | 212.66 | 144.79 | 251.44 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $2 |
| EBITDA | $22 | $13 | $9 | $16 |
| % Margin | 23.4% | 17.4% | 12.9% | 21.5% |